2024
A Minimalist Pathogen‐Like Sugar Nanovaccine for Enhanced Cancer Immunotherapy
Miao Y, Niu L, Lv X, Zhang Q, Xiao Z, Ji Z, Chen L, Liu Y, Liu N, Zhu J, Yang Y, Chen Q. A Minimalist Pathogen‐Like Sugar Nanovaccine for Enhanced Cancer Immunotherapy. Advanced Materials 2024, 36: e2410715. PMID: 39210649, DOI: 10.1002/adma.202410715.Peer-Reviewed Original ResearchCancer immunotherapyMaturation of antigen-presenting cellsVaccine carriersImmune checkpoint blockade therapyAntigen-specific immune responsesInhibition of tumor growthCheckpoint blockade therapyEnhanced cancer immunotherapyAntigen-presenting cellsVaccine delivery technologiesB16-OVABlockade therapyImmune activationTumor modelTumor growthAntigen loadNanovaccineImmune responseMeticulous screeningAntigenic peptidesImmunostimulatory characteristicsChain ratioDelivery technologiesImmunotherapyIn vivoMinimalist Nanovaccine with Optimized Amphiphilic Copolymers for Cancer Immunotherapy
Niu L, Miao Y, Cao Z, Wei T, Zhu J, Li M, Bai B, Chen L, Liu N, Pan F, Zhu J, Wang C, Yang Y, Chen Q. Minimalist Nanovaccine with Optimized Amphiphilic Copolymers for Cancer Immunotherapy. ACS Nano 2024, 18: 3349-3361. PMID: 38230639, DOI: 10.1021/acsnano.3c10174.Peer-Reviewed Original ResearchConceptsTumor-specific immune responsesBone marrow-derived dendritic cellsCancer immunotherapyDendritic cellsCancer vaccinesActivate tumor-specific immune responsesCell death protein ligand 1Mouse bone marrow-derived dendritic cellsImmune responseMarrow-derived dendritic cellsAnti-PD-L1Codelivery of antigenEffective cancer vaccinesPre-existing tumorsActivated dendritic cellsAntigen cross-presentationDC maturationCross-presentationTumor modelProphylactic efficacyNanovaccineImmune effectsImmunotherapyPeptide antigensCancer
2023
A coordinative dendrimer-based nanovaccine for cancer treatment
Cao Z, Ren L, Niu L, Zhao R, Liu N, Zhuang Q, Pan F, Liu Z, Cheng Y, Yang Y, Chen Q. A coordinative dendrimer-based nanovaccine for cancer treatment. Matter 2023, 6: 3574-3597. DOI: 10.1016/j.matt.2023.08.001.Peer-Reviewed Original ResearchCancer vaccinesCancer immunotherapyDendritic cellsField of cancer immunotherapyTumor-specific immune responsesEffective cancer immunotherapyAnti-PD-L1Efficient antigen cross-presentationAntigen cross-presentationCGAS-STING pathwayCross-presentationImmune responseCancer cellsTherapeutic effectCancer treatmentCancerCGAS-STINGImmunotherapyVaccinePeptide carrierCellsNanovaccineNeoantigensPeptidePatients